KalVista Pharmaceuticals (KALV) News Today $12.02 +0.07 (+0.59%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$12.02 +0.01 (+0.04%) As of 04/15/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by American Century Companies Inc.American Century Companies Inc. trimmed its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 71.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,072 sApril 16 at 3:12 AM | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Buys $235,500.00 in StockApril 12, 2025 | insidertrades.comKalVista: Poised For Rare Disease TransformationApril 12, 2025 | seekingalpha.comKalVista Pharmaceuticals (NASDAQ:KALV) Trading Down 7.2% - Here's What HappenedKalVista Pharmaceuticals (NASDAQ:KALV) Shares Down 7.2% - Here's WhyApril 10, 2025 | marketbeat.comKalVista Pharmaceuticals' (KALV) Buy Rating Reiterated at Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a research note on Tuesday.April 10, 2025 | marketbeat.comKalVista subsidiary licenses commercialization rights for sebetralstat in JapanApril 9, 2025 | markets.businessinsider.comKalVista Pharmaceuticals (NASDAQ:KALV) Shares Up 8.3% - Should You Buy?KalVista Pharmaceuticals (NASDAQ:KALV) Shares Up 8.3% - Still a Buy?April 9, 2025 | marketbeat.comKalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in JapanApril 8, 2025 | uk.finance.yahoo.comKalVista licenses commercialisation rights for HAE to Kaken in JapanApril 8, 2025 | finance.yahoo.comKalVista rises after licensing deal with Kaken for lead asset in JapanApril 8, 2025 | msn.comKalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Up 8.3% - Here's What HappenedApril 8, 2025 | americanbankingnews.comAnalyzing CNS Pharmaceuticals (NASDAQ:CNSP) & KalVista Pharmaceuticals (NASDAQ:KALV)April 7, 2025 | americanbankingnews.comSchroder Investment Management Group Acquires 374,213 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)Schroder Investment Management Group grew its holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 86.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 805,445 shares of the specialty pharmaceutical company's stock afterApril 6, 2025 | marketbeat.comKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 2, 2025 | businesswire.comKalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare ConferenceMarch 31, 2025 | businesswire.comQ4 Earnings Forecast for KALV Issued By Leerink PartnrsKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - Equities research analysts at Leerink Partnrs issued their Q4 2025 EPS estimates for shares of KalVista Pharmaceuticals in a note issued to investors on Tuesday, March 25th. Leerink Partnrs analyst J. Schwartz forecasts that the specialMarch 29, 2025 | marketbeat.comKalVista completes enrollment in KONFIDENT-KID clinical trial of sebetralstatMarch 27, 2025 | markets.businessinsider.comKalVista Pharmaceuticals (NASDAQ:KALV) Given Buy Rating at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a research report on Wednesday.March 27, 2025 | marketbeat.comStifel Nicolaus Keeps Their Buy Rating on KalVista Pharmaceuticals (KALV)March 27, 2025 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on KalVista Pharmaceuticals (KALV)March 27, 2025 | markets.businessinsider.comKalVista Pharmaceuticals (NASDAQ:KALV) Earns "Buy" Rating from Jones TradingJones Trading restated a "buy" rating and issued a $30.00 price objective on shares of KalVista Pharmaceuticals in a report on Wednesday.March 27, 2025 | marketbeat.comKalVista Pharmaceuticals enrols all subjects in hereditary angioedema drug trialMarch 26, 2025 | finance.yahoo.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Consensus Recommendation of "Buy" by AnalystsKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) has been assigned an average recommendation of "Buy" from the seven brokerages that are currently covering the stock, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating and one has issued a strong bMarch 23, 2025 | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Down 3% - Here's WhyKalVista Pharmaceuticals (NASDAQ:KALV) Shares Down 3% - Time to Sell?March 20, 2025 | marketbeat.comKalVista Pharmaceuticals' (KALV) Buy Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday.March 15, 2025 | marketbeat.comKalVista Pharmaceuticals' (KALV) "Buy" Rating Reiterated at Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $28.00 price objective on shares of KalVista Pharmaceuticals in a research report on Thursday.March 14, 2025 | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Releases Earnings Results, Misses Estimates By $0.03 EPSKalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) issued its earnings results on Wednesday. The specialty pharmaceutical company reported ($0.92) EPS for the quarter, missing analysts' consensus estimates of ($0.89) by ($0.03).March 13, 2025 | marketbeat.comInsider Selling: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Sells 6,669 Shares of StockKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) CEO Benjamin L. Palleiko sold 6,669 shares of the company's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $11.97, for a total transaction of $79,827.93. Following the transaction, the chief executive officer now directly owns 287,811 shares of the company's stock, valued at $3,445,097.67. This represents a 2.26 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.March 11, 2025 | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko Sells 6,669 SharesMarch 11, 2025 | insidertrades.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Short Interest Down 18.2% in FebruaryKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) saw a large decline in short interest during the month of February. As of February 15th, there was short interest totalling 5,830,000 shares, a decline of 18.2% from the January 31st total of 7,130,000 shares. Based on an average daily volume of 371,600 shares, the days-to-cover ratio is currently 15.7 days.March 5, 2025 | marketbeat.comKalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual MeetingMarch 3, 2025 | finance.yahoo.comKalVista Pharmaceuticals (KALV) to Release Quarterly Earnings on MondayKalVista Pharmaceuticals (NASDAQ:KALV) will be releasing earnings before the market opens on Monday, March 10, Financial Modeling Prep reports.March 3, 2025 | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Paul K. Audhya Sells 2,394 SharesKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) insider Paul K. Audhya sold 2,394 shares of the business's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $10.02, for a total transaction of $23,987.88. Following the sale, the insider now owns 102,940 shares in the company, valued at $1,031,458.80. This represents a 2.27 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.February 26, 2025 | marketbeat.comPaul K. Audhya Sells 2,394 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) StockFebruary 26, 2025 | insidertrades.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Recommendation of "Buy" from AnalystsShares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) have been assigned a consensus rating of "Buy" from the seven research firms that are currently covering the company, MarketBeat reports. Six analysts have rated the stock with a buy rating and one has assigned a strong buyFebruary 25, 2025 | marketbeat.comKalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual MeetingFebruary 21, 2025 | uk.finance.yahoo.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Paul K. Audhya Sells 3,125 SharesKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) insider Paul K. Audhya sold 3,125 shares of the company's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $9.82, for a total value of $30,687.50. Following the sale, the insider now owns 100,334 shares of the company's stock, valued at $985,279.88. This trade represents a 3.02 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.February 20, 2025 | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko Sells 5,104 SharesKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) CEO Benjamin L. Palleiko sold 5,104 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total transaction of $50,121.28. Following the sale, the chief executive officer now directly owns 278,855 shares of the company's stock, valued at $2,738,356.10. This represents a 1.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.February 20, 2025 | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Trading Up 8.7% - What's Next?KalVista Pharmaceuticals (NASDAQ:KALV) Shares Up 8.7% - Time to Buy?February 20, 2025 | marketbeat.comTD Cowen Remains a Buy on Supernus Pharmaceuticals (SUPN)February 20, 2025 | markets.businessinsider.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Sells $30,687.50 in StockFebruary 20, 2025 | insidertrades.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Short Interest UpdateKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) was the recipient of a significant drop in short interest during the month of January. As of January 31st, there was short interest totalling 7,130,000 shares, a drop of 6.1% from the January 15th total of 7,590,000 shares. Based on an average daily volume of 368,500 shares, the short-interest ratio is presently 19.3 days.February 18, 2025 | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Venrock Healthcare Capital Par Acquires 100,000 SharesKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) major shareholder Venrock Healthcare Capital Par acquired 100,000 shares of the business's stock in a transaction on Wednesday, February 12th. The stock was acquired at an average price of $9.23 per share, with a total value of $923,000.00. Following the transaction, the insider now directly owns 5,217,285 shares of the company's stock, valued at $48,155,540.55. This represents a 1.95 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.February 15, 2025 | marketbeat.comVenrock Healthcare Capital Par Purchases 100,000 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) StockFebruary 15, 2025 | insidertrades.comKalVista Pharmaceuticals sees $1.5m stock purchase by VenrockFebruary 15, 2025 | msn.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Acquires $37,812.18 in StockFebruary 12, 2025 | insidertrades.comInsider Buying: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Purchases 4,137 Shares of StockKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) major shareholder Venrock Healthcare Capital Par acquired 4,137 shares of KalVista Pharmaceuticals stock in a transaction on Monday, February 10th. The shares were purchased at an average cost of $9.14 per share, with a total value of $37,812.18. Following the completion of the purchase, the insider now directly owns 5,090,582 shares of the company's stock, valued at approximately $46,527,919.48. This represents a 0.08 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.February 11, 2025 | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Venrock Healthcare Capital Par Purchases 73,649 Shares of StockKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) major shareholder Venrock Healthcare Capital Par purchased 73,649 shares of the company's stock in a transaction that occurred on Friday, February 7th. The shares were purchased at an average price of $9.29 per share, with a total value of $684,199.21. Following the completion of the transaction, the insider now directly owns 5,086,445 shares of the company's stock, valued at $47,253,074.05. This represents a 1.47 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.February 11, 2025 | marketbeat.comJMP Securities Sticks to Their Buy Rating for KalVista Pharmaceuticals (KALV)February 11, 2025 | markets.businessinsider.comKalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual MeetingFebruary 10, 2025 | finance.yahoo.com Remove Ads Get KalVista Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter. Email Address KALV Media Mentions By Week KALV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KALV News Sentiment▼0.750.79▲Average Medical News Sentiment KALV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KALV Articles This Week▼83▲KALV Articles Average Week Remove Ads Get KalVista Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TWST News MLTX News AMRX News RXRX News VCEL News MIRM News SDGR News DNLI News MTSR News BHVN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KALV) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KalVista Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KALV Stock Free KALV Stock Alerts